Patents by Inventor Balakrishna Reddy SIRIGIREDDY

Balakrishna Reddy SIRIGIREDDY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220259204
    Abstract: The present invention relates to a process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b] pyridin-5-yloxy)benzamide) compound of formula-1 which is represented by the following structural formula:
    Type: Application
    Filed: July 8, 2020
    Publication date: August 18, 2022
    Inventors: Balakrishna Reddy SIRIGIREDDY, Veeraswamy BALINA, Sreenivas RACHAKONDA, Veerender MURKI, Durga Prasad KONAKANCHI, Pulla Reddy MUDDASANI, Venkaiah Chowdary NANNAPANENI
  • Patent number: 10047088
    Abstract: The present invention relates to novel antiproliferative 1H-1, 8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: August 14, 2018
    Assignee: NATCO PHARMA LIMITED
    Inventors: Amala Kompella, Venugopala Krishna Gampa, Srinivasulu Ganganamoni, Balakrishna Reddy Sirigireddy, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • Publication number: 20170349588
    Abstract: The present invention relates to novel antiproliferative 1H-1, 8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Application
    Filed: August 18, 2017
    Publication date: December 7, 2017
    Inventors: Amala KOMPELLA, Venugopala Krishna GAMPA, Srinivasulu GANGANAMONI, Balakrishna Reddy SIRIGIREDDY, Kali Satya Bhujanga Rao ADIBHATLA, Venkaiah Chowdary NANNAPANENI
  • Patent number: 9765072
    Abstract: The present invention relates to novel antiproliferative 1H-1, 8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: September 19, 2017
    Assignee: NATCO PHARMA LIMITED
    Inventors: Amala Kompella, Venugopala Krishna Gampa, Srinivasulu Ganganamoni, Balakrishna Reddy Sirigireddy, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • Publication number: 20170114057
    Abstract: The present invention relates to novel antiproliferative 1H-1,8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 27, 2017
    Inventors: Amala KOMPELLA, Venugopala Krishna GAMPA, Srinivasulu GANGANAMONI, Balakrishna Reddy SIRIGIREDDY, Kali Satya Bhujanga Rao ADIBHATLA, Venkaiah Chowdary NANNAPANENI